Clinical Trial Update: A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay

View source ↗

Summary

A completed prospective observational study evaluated clinical outcomes associated with the Prosigna gene signature assay in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: NanoString Technologies, Inc. | Conditions: Breast Cancer | Status: COMPLETED